Platelet Heterogeneity in Myeloproliferative Neoplasms

Arterioscler Thromb Vasc Biol. 2021 Nov;41(11):2661-2670. doi: 10.1161/ATVBAHA.121.316373. Epub 2021 Oct 7.

Abstract

Myeloproliferative neoplasms (MPNs) are a group of malignant disorders of the bone marrow where a dysregulated balance between proliferation and differentiation gives rise to abnormal numbers of mature blood cells. MPNs encompass a spectrum of disease entities with progressively more severe clinical features, including complications with thrombosis and hemostasis and an increased propensity for transformation to acute myeloid leukemia. There is an unmet clinical need for markers of disease progression. Our understanding of the precise mechanisms that influence pathogenesis and disease progression has been limited by access to disease-specific cells as biosources. Here, we review the landscape of MPN pathology and present blood platelets as potential candidates for disease-specific understanding. We conclude with our recent work discovering progressive platelet heterogeneity by subtype in a large clinical cohort of patients with MPN.

Keywords: blood platelets; bone marrow; hemostasis; myelofibrosis; polycythemia vera; thrombosis; transcriptome.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Blood Coagulation
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism*
  • Blood Platelets / pathology
  • Humans
  • Molecular Targeted Therapy
  • Myeloproliferative Disorders / blood*
  • Myeloproliferative Disorders / drug therapy
  • Myeloproliferative Disorders / genetics
  • Myeloproliferative Disorders / pathology
  • Phenotype
  • Platelet Activation* / drug effects
  • Platelet Aggregation Inhibitors / therapeutic use
  • Thrombopoiesis* / drug effects

Substances

  • Antineoplastic Agents
  • Platelet Aggregation Inhibitors